Thatsall101
hi
- Joined
- Apr 11, 2026
- Posts
- 488
- Reputation
- 334
based off toxicity
we all know erda is the most toxic fgfr3 inhibi, however we all know of other options such as (tyra300, infig, visorotide etc)
enter LOXO-435
an fgfr3 inhibitor with more human clinical data than tyra300 and much much less sides than even tyra300 (all sources in the bottom of this text)
most impressively compared to tyra300 where studies had to be halted at times due to "severe adverse events", (10% of the time)
"No dose-limiting toxicities (DLTs) were observed across dose levels ranging from 6 mg once daily up to 400 mg twice daily."
for LOXO-435
www.ovid.com
clinicaltrials.gov
https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.662 (in pdf look down and download it)
————
lazy post again, just wanted your opinion boyos
we all know erda is the most toxic fgfr3 inhibi, however we all know of other options such as (tyra300, infig, visorotide etc)
enter LOXO-435
an fgfr3 inhibitor with more human clinical data than tyra300 and much much less sides than even tyra300 (all sources in the bottom of this text)
most impressively compared to tyra300 where studies had to be halted at times due to "severe adverse events", (10% of the time)
"No dose-limiting toxicities (DLTs) were observed across dose levels ranging from 6 mg once daily up to 400 mg twice daily."
for LOXO-435
A first-in-human phase 1 study of LY3866288... : Journal of Clinical Oncology
662Background: Activating alterations in FGFR3 (most commonly S249C) occur in 15-20% of metastatic urothelial cancers (mUC) and FGFR3-altered mUC but...
ClinicalTrials.gov
https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.662 (in pdf look down and download it)
————
lazy post again, just wanted your opinion boyos